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Abstract 
 
Aims. To assess the prevalence of elevated liver enzymes in adults with type 1 
diabetes mellitus (T1DM) in routine clinical care and the association with 
cardiovascular risk profile in the Diabetes-Prospective-Documentation (DPV) 
network in Germany and Austria. 
Methods. This cross sectional observational study from the DPV registry includes 
data from 45519 adults with T1DM at 478 centers up to 9/2016. Liver enzyme 
measurements were available in 9226 (29%) patients at 270 centers and were 
analyzed for increased alanine aminotransferase (ALT; men>50 U/l, women: >35U/l) 
and/or aspartate aminotransferase (AST; men >50 U/l, women >35U/l) and/or 
gamma-glutamyltransferase (GGT; men >60U/l, women>40 U/l). A subgroup 
analysis in patients in whom two or more ALT measurements were available 
(n=2335, 25%) and whose ALT was increased at least twice (men:>30 U/l, women 
>19U/) was performed. Associations with glycemic control, cardiovascular risk 
factors and late complications were investigated with multiple regression analyses. 
Results. Twenty percent (19.8%, n=1824) had increased liver enzyme(s) on one or 
more occasions. Increased liver enzymes were associated with worse glycemic control 
and higher BMI (both p<0.0001), dyslipidemia (OR:1.75, 95%CI: 1.54-2.0), 
hypertension (OR:1.48, 95%CI:1.31-1.68), myocardial infarction (OR:1.49; 
95%CI:1.17-1.91) and end stage renal disease (OR:1.59; 95%CI:1.17-2.17). ALT was 
increased twice in 29% and was associated with worse glycemic control (p<0.0001), 
higher BMI (p<0.0001), hypertension (OR:1.58, 95%CI:1.26-1.97) and dyslipidemia 
(OR:1.89, 95%CI:1.51-2.37).  
Conclusions. In this clinical audit in adults with T1DM, elevated liver enzymes on 
routine assessment were associated with a less favorable cardiovascular risk profile 
and with poorer glycemic control.  
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Abbreviations:  
T1DM- type 1 diabetes mellitus 
DPV- Diabetes-Prospective-Documentation network in Germany and Austria 
ALT- alanine aminotransferase  
AST- aspartate aminotransferase  
GGT- gamma-glutamyl transferase  
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Introduction 
The clinical management of Type 1 diabetes mellitus (T1DM) focuses on preventing 
and treating acute as well as chronic complications by optimizing glycemic control 
and tackling additional risk factors. This includes routine screening for nephropathy, 
retinopathy and neuropathy to allow early secondary prevention [1]. Annual 
assessment of liver function is recommended in diabetes clinical practice guidelines 
[1] because diabetes mellitus doubles the risk for chronic non alcoholic fatty liver 
disease (NAFLD) and hepatocellular carcinoma [2, 3]. Type 2 diabetes and NAFLD 
share insulin resistance/hyperinsulinemia as underlying pathophysiology, therefore 
NAFLD is a well documented comorbidity of type 2 diabetes [4-6].  
In contrast, the clinical significance of measuring liver enzymes in T1DM as part of 
the annual screening for complications is unclear: T1DM is an autoimmune condition 
with absolute insulin deficiency and is not per se usually accompanied by features of 
metabolic syndrome. However, the prevalence of the metabolic syndrome is 
increasing in both the general population, and in people with T1DM [7]. The 
cardiovascular risk profile in people with T1DM demands prescription of drugs that 
can have hepatotoxic side effects.  
The real-life clinical practice of routinely measuring liver enzymes as well as the 
prevalence of increased liver enzymes in people with T1DM in routine clinical care, 
have not as yet been documented in larger surveys. Therefore it seemed timely to 
assess the prevalence of elevated liver enzymes in adults with T1DM in a cross 
sectional multicenter and multinational clinical audit database. Further we wanted to 
investigate associations between increased liver enzymes, glycemic control, 
cardiovascular risk profile and diabetes late complications in people with T1DM.  
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Subjects and Methods 
 
Data collection. 
The German/Austrian Diabetes Patienten Verlaufsdokumentation (DPV) prospective 
documentation system is a nationwide multicentre survey [8] founded in 1990, 
comprising up until September 2016 data from 452508 patients. 
The individual centers enter their patient data into a standardized electronic patient 
record. The anonymized data sets are exported biannually to the central database in 
Ulm, Germany, where the data and diagnoses undergo a plausibility check and queries 
are returned to participating centers. Once the queries have been resolved the data are 
aggregated into a cumulative database for clinical research and quality assurance. The 
DPV database is a resource for clinical quality management and benchmarking as 
well as for research . 
All people with T1DM over the age of 20 years, in whom insulin therapy was clearly 
documented, were considered for this analysis. People with type 2 diabetes, people 
with other forms of diabetes (secondary to e.g. cystic fibrosis or hemochromatosis, 
gestational diabetes) were excluded. Of the 111498 people with T1DM in the DPV 
registry, there were 45519 adults with T1DM over the age of 20 years. Liver enzymes 
had to be measured at least once in the previous 12 months (from the date of data 
extraction). Patients with a history of hepatitis, celiac disease, alpha-1-antitrypsin 
deficiency, alcoholism and persons consuming >=24g (males) or >=12g (females) 
alcohol per day were excluded from the analysis as per national recommendations for 
maximum alcohol consumption 
(http://www.drinkingandyou.com/site/pdf/Sensibledrinking.pdf).  
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History of celiac disease was an exclusion criterion, because celiac disease per se can 
be associated with increased liver transaminases [9]. A detailed flow-chart is provided 
in figure 1. 
The analyses of the anonymized routine clinical data within the German/Austrian 
Diabetes Prospective Documentation Initiative (DPV) have been approved by the 
Ethics Committee of the Medical Faculty of the University of Ulm and the local 
institutional review boards. 
The data forming the basis of this report are anthropometry (age, sex, body mass 
index, waist circumference, diabetes duration), diabetes therapy modality 
(conventional insulin therapy- i.e. twice daily mix-insulin, intensified insulin therapy 
according to basis-bolus-principle, continuous subcutaneous insulin infusion with 
insulin pumps), general data on medication and self reported alcohol intake. 
Migration background was defined as having either a mother and/or a father who was 
not born in Austria or Germany. Laboratory data were derived from each center’s 
local routine laboratory measurements and included HbA1c, lipid profile and liver 
enzymes [including Alanine aminotransferase (ALT), aspartate aminotransferase 
(AST) and γ-glutamyl transferase (GGT)]. Local HbA1c values were mathematically 
standardized to the Diabetes Control and Complications Trial (DCCT) reference range 
(20-42mmol/l; 4.05-6.05%) using the multiple-of-the-mean transformation method 
[10, 11]. 
 
Data analyses. 
Increased liver enzymes 
Increased liver enzymes were defined as one or more measurement of: 
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Alanine aminotransferase (ALT) >50 U/l in men/ >35 U/l in women, aspartate 
aminotransferase (AST) >50 U/l in men/ >35 U/l in women and/or γ-glutamyl 
transferase (GGT) >60 U/l in men/>40 U/l, according to the definition of the German 
Liver Foundation (http://www.deutsche-leberstiftung.de/check-up/GPT-Faltblatt-
0109-NETZ.pdf).  
An additional analysis was performed with lower cut-off values for ALT (males >=30 
U/L and females (>=19 U/L) [12], categorizing those patients into the group of T1DM 
with increased ALT, whose ALT was above this threshold in at least two 
measurements.  
Comorbidities and complications. 
Hypertension was defined by the use of antihypertensive medication or by increased 
systolic (>=140mmHg) and/or diastolic (>=90mmHg) arterial blood pressure 
according to current guidelines [13]. Dyslipidemia was defined as either taking lipid 
modifying drugs or having decreased high-density lipoprotein (HDL) cholesterol 
values (<35mg/dl), or by at least one increased value of total cholesterol (>200mg/dl), 
low density lipoprotein (LDL) cholesterol (>130mg/dl), or triglycerides (>150mg/dl) 
values.  
Data on prevalence of late complications including end stage renal disease, 
myocardial infarction, stroke, or major lower limb amputation were available from the 
DPV database. End stage renal disease was defined as either having received a renal 
transplantation, being on hemo- or peritoneal dialysis treatment, or a calculated eGFR 
below 15ml/min/1.73 [14]. 
 
In order to address the issue of potential heterogeneity between centers as to the 
frequency with which they are measuring liver enzymes, we conducted two additional 
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analyses to better understand the data set available: We compared data from centers in 
which liver enzymes were measured in more than 50% of their patients with data from 
centers that conduct less frequent measurements.  
A comparison was made between patients in whom liver enzymes were available and 
those patients whose liver enzymes were not measured/ reported. The results are 
provided as supplemental material. 
 
Statistical analyses were performed using the software package SAS version 9.4 
(Statistical Anlaysis Software, SAS Institute; Cary, NC). Sociodemographic and 
clinical characteristics are presented as median and interquartile range (Q1,Q3) or as 
percentage, unless stated otherwise.  Two-sided p value of <0.05 was considered to be 
significant. For group comparison, Wilcoxon testing for continuous and Χ
2
 tests for 
categorical data were used. The Holm method was applied to adjust p-values for 
multiple comparisons. Multiple logistic regression models for dichotomous variables 
(prevalence of hypertension, dyslipidemia, macrovascular complications and end 
stage renal disease) and multiple linear regression analyses for continuous variables 
(age, BMI, HbA1c, insulin doses) were applied for adjustment.  
 
Results 
Data on liver enzymes from the previous 12 months were available from 270 centres. 
A total of 9226 patients (29%) of the 32075 patients fulfilling the inclusion criteria 
had their liver transaminases measured and reported at least once in the 12 months 
observation period (Figure 1). Of the 270 centers that were reporting liver enzyme 
measurements in their patients, 83 centres measured liver enzymes in at least 50% of 
their patients (Table 4, supplemental material).  
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Total cohort. 
More than half (56%) of the patients were using intensified basis bolus insulin therapy 
using insulin pens, an additional 29% were using insulin pumps and 15% were on 
conventional insulin therapy. In this cohort there is a high proportion of well-
controlled patients (40% with an HbA1c below or equaling 7.5%), but 33% have an 
HbA1c above 9% (Table 1, third column). 
Of the 9226 patients, 1824 (19.8%) had increased liver enzymes in one or more 
measurement(s), of which 1254 (69%) had increased GGT, 870 (48%) had increased 
ALT and 566 (31%) increased AST. In 243 (13%) patients all three liver enzymes 
were increased.  
Hypertension was present in 47% (38% on antihypertensive drugs) and dyslipidemia 
in 63% (21% on lipid lowering drugs). A history of myocardial infarction was present 
in 3.9%, 2.8% had suffered a stroke, 0.7% had a major limb amputation and 2.7% had 
end stage renal disease (Table 1, third column). 
 
Subgroup comparison between patients with increased and normal liver enzymes. 
Characteristics of both groups are shown in the fourth and fifth columns of Table 1. 
Patients with increased liver enzymes were older, had a higher BMI (both p values 
<0.0001) and larger waist circumference (p<0.0005) than the patients with normal 
liver enzymes, while duration of diabetes, sex distribution and proportion of people 
with background of migration did not differ (Table 1). The group with increased liver 
enzymes had worse glycemic control (p<0.00001), a higher proportion of patients 
using conventional insulin therapy and a lower proportion of patients using intensified 
or insulin pump therapy than in those with normal liver enzyme levels (all p<0.01) 
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(Table 1). Lipid modifying drugs were taken by 19% in the group with normal liver 
enzymes and 29% in the group with increased liver enzymes (both p<0.00001). 
 
After adjustment for age, sex, HbA1c, diabetes duration, migration background and 
treatment center in linear regression models, age, BMI, HbA1c and the daily insulin 
per body weight doses were significantly higher in the group with increased liver 
enzymes than in the group with normal liver enzyme measurements (all adjusted 
values are presented in Table 2; corresponding p-values <0.0001, Table 2). In logistic 
regression models adjusting for age, sex, HbA1c, diabetes duration, migration 
background and treatment center, people with increased liver enzymes were more 
likely to have hypertension (OR: 1.48, 95% CI:1.31-1.68) and dyslipidemia (OR 1.75, 
95% CI: 1.54-2.00) and more likely to have had a myocardial infarction and to have 
end stage renal disease (OR were 1.5 and 1.6, respectively, Table 2), but there was no 
association with the prevalence of history of stroke or major amputations (Table 2). 
 
Subgroup comparison between patients with increased ALT and normal ALT. 
Two (or more) ALT measurements per patient were available in a subgroup of 2335 
patients (25%). ALT was increased at least twice in 686 (29%) of these patients. 
Patients with increased ALT were older, had a higher BMI and waist circumference, 
had a higher HbA1c and a more adverse lipid profile (Table 3, supplemental 
material). After adjustment for age, sex, HbA1c, diabetes duration, migration 
background and treatment center in linear and logistic regression models, patients 
with ALT were more likely to have hypertension (OR 1.58, 95% CI: 1.26-1.97) and 
dyslipidemia (OR 1.89, 95% CI: 1.51-2.37), to be older and have a higher HbA1c and 
BMI (Table 4, supplemental material), but there were no differences in prevalence of 
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myocardial infarction, stroke, major amputation or end stage renal disease (Table 4, 
supplemental material).  
 
When comparing the group of patients who were included based on the criteria above 
(see methods section) and the availability of liver enzyme measurements (n=9226) 
with those who fulfilled all inclusion criteria but had no liver enzyme measurements 
available (n= 22849), the patients with available liver enzyme measurements were 
younger, had a higher proportion of people with migration background, had a higher 
BMI and waist circumference, higher HbA1c and daily insulin doses, lower 
triglyceride levels and lower blood pressure (Table 5, supplemental material). The 
prevalences of MCI, stroke, end stage renal disease were not different, but the 
prevalence of hypertension and dyslipidemia was higher in the patients in whom liver 
enzymes have been reported (Table 5, supplemental material). 
 
The comparison between patients from centers in which liver enzymes were measured 
in >50% of the patients (n= 5073, 55%) and those coming from centers with less 
frequent liver enzyme measurements  (n=4153, 45%) showed that patients from 
centers with frequent liver enzyme measurements had a longer duration of diabetes, a 
higher proportion with migration background, higher HbA1c and systolic blood 
pressure (Table 6, supplemental material). When analyzing only data from centers 
that measure frequently, the proportion of patients with increased liver enzymes was 
19.4%, which is similar to the proportion reported in the total dataset (19.8%). The 
prevalence of MCI, stroke and major amputation did not differ, but there was a higher 
prevalence of end stage renal disease and hypertension in patients treated at centers 
with frequent measurement of liver enzymes (Table 6, supplemental material).
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Discussion 
In this report we describe the prevalence of increased liver enzymes in a multicenter 
audit of 45519 adults with T1DM in routine clinical care. After exclusion of people 
with health factors known to influence hepatic function, liver enzyme measurements 
were available in 29% of the patients. Of these, 20% had increased liver enzymes 
during the course of routine clinical follow up. Elevation of liver enzymes was 
associated with worse glycemic control, less favorable cardiovascular risk profile and 
a higher prevalence of diabetes late complications (myocardial infarction and end 
stage renal failure).  
 
For reports such as this to be useful to practicing clinicians, it is essential to put them 
in context. The prevalence of increased liver enzymes observed here compares to 
estimates of 10-21% in the general population [15-17] and 12% to 71% in Type 2 
diabetes [18-21]. Comparing the results from our study with data from the general 
population is difficult because the latter will, for example, include individuals with 
undiagnosed liver pathologies, or individuals consuming alcohol in excess of the 
recommended levels. In contrast, we have excluded from our analyses people with 
known liver pathologies and excessive alcohol consumption. Further, people with an 
established diagnosis of T1DM are more likely to be taking statin therapy by virtue of 
the awareness of diabetes physicians of the cardiovascular risk. 
A smaller observational study in approximately 900 patients with T2DM and T1DM 
noted that increased ALT was increased in 2-35% of T1DM and 4-51% in T2DM, 
depending on the cut-off used [22]. In their subgroup with patients with T1DM 
applying the same lower ALT threshold as we have used in our subgroup analysis, the 
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35% of patients had increased ALT was 35%, which is a higher proportion than in our 
cohort [22].  
Another issue that arises in the analyses of large datasets is that no clear consensus 
exists as to where to set the cut-off thresholds for increased liver enzymes in T1DM, 
such that the proportion of people with increased measurements depends on the 
diagnostic threshold applied. We have used different diagnostic criteria within the 
same DPV dataset, one applying national liver association guidelines and one using 
lower ALT cut-off but in two measurements as suggested elsewhere [12]. Using these 
two approaches the proportions of patients with elevated liver enzymes changes from 
20 to 29%. However, the association with poorer glycemic control and less favorable 
cardiovascular risk profile (dyslipidemia and hypertension) was consistent in both 
analyses, whereas the association with diabetes complications (myocardial infarction 
and end stage renal disease) was only significant in the analysis applying the higher 
liver enzyme cut off thresholds of the national guidelines. This would suggest that a 
lower ALT cut-off has the potential to identify patients with higher cardiovascular 
risk at an earlier stage. 
 
In the present cross sectional analysis in people with T1DM in the DPV registry, the 
group with increased liver enzymes had a more adverse cardiovascular risk profile 
with a high prevalence of hypertension and dyslipidemia and worse glycemic control 
than those with normal liver enzymes. Patients with elevated liver enzymes were also 
more obese, suggesting a higher level of insulin resistance. Notably, the odds ratios 
for myocardial infarction and end stage renal disease were 1.5 and 1.6, respectively, 
when compared with the patients with normal liver enzymes and after adjustment for 
age, HbA1c and other factors. This is in line with observations from a large, 
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population-based, longitudinal study that suggested an association between elevated 
GGT levels and all-cause and cardiovascular mortality in men [23] , and from smaller 
clinic-based reports in people with T1DM in whom NAFLD was associated with  an 
increased incidence of chronic kidney disease [24] and with a greater prevalence of 
retinopathy and nephropathy [25].   
Given the audit-style nature of this report it is not possible to determine whether the 
increased rates of diabetes complications in the patients with T1DM who have 
increased liver enzymes are a consequence of shared conventional risk factors 
(hypertension, dyslipidemia, hyperglycemia), or whether the increased liver enzymes 
represent an independent risk marker in this situation. The former seems more likely.  
Further, longitudinal observational studies will be needed to better understand the 
relationship between increased liver enzymes and comorbidities and complications in 
people with T1DM and to determine the diagnostic thresholds for increased liver 
enzymes clinically relevant for people with T1DM. 
 
Although the DPV has the potential to provide insight into routine clinical practice by 
virtue of its size, our study has obvious limitations. First, the real-world character of a 
clinical database is apparent in the 29% of patients in whom liver enzyme 
measurements were available. This heterogeneity of clinical practice between centers 
has the potential to introduce bias into our dataset. Patients who did not have their 
liver enzymes reported were younger, leaner, had a better diabetes control and lower 
prevalence of hypertension and dyslipidemia, which may have contributed to an 
individual clinician’s decision not to measure liver enzymes.  
The additional comparison made between patients from centers that measure liver 
enzymes in over 50% of their patients and patient from centers that measure in less 
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than 50% of patients confirmed that patients from centers with frequent liver enzyme 
measurements had a longer diabetes duration, worse diabetes control, more likely to 
have a migration background and had a higher prevalence of hypertension and end 
stage renal disease, which altogether may have contributed to local clinical routine 
standards more in favor of a risk factor assessment including liver enzymes. 
  
Conclusion. 
In this clinical audit in adults with T1DM, elevated liver enzymes on routine clinical 
assessment were associated with a less favorable cardiovascular risk profile and 
poorer glycemic control. We consider these observations worthy of reporting as they 
may, if supported by future longitudinal studies from other groups, provide an 
additional factor in the cardiovascular risk stratification of people with T1DM. 
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Legends to Figures 
 
Figure 1. 
Flow chart of patient inclusion and exclusion for the final analysis. 
DPV, Diabetes Prospective Documentation; ALT, alanine-aminotransferase; AST, aspartate-
aminotransferase; GGT, gamma-glutamyl transferase. 
 
 
Legends to Tables. 
 
Table 1.  
Anthropometric, clinical and laboratory characteristics of patients with T1DM with 
increased ALT, AST and/or GGT compared with patients with normal ALT, AST and 
GGT and prevalence of diabetes late complications and comorbidities (un-adjusted 
percentages). 
Data are presented as median (Q1, Q3). P-values for subgroup comparisons for 
continuous variables are derived from non-parametric testing applying Wilcoxon tests 
and from χ
2
 tests for binominally distributed variables. P values adjusted for multiple 
comparisons using the Holm method. 
T1DM, type 1 diabetes mellitus; BMI, body mass index; HbA1c, glycated Hemoglobin A1c; BP, blood 
pressure; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; GGT, gamma-glutamyl-
transferase; LDL-cholesterol, low-density lipoprotein cholesterol; HDL-cholesterol, high density 
lipoprotein cholesterol; 
 
Table 2.  
Comparison of prevalence of comorbidities and complications by means of logistic 
regression models (with adjustment for age, sex, diabetes duration, migration 
background, HbA1c and treatment center) and comparison of age, BMI, insulin doses 
and HbA1c using linear regression models (*) (with adjustement for age, sex, diabetes 
duration, migration background, HbA1c and treatment center) between patients with 
increased and with normal liver enzymes.  
Data are presented as means ± standard error of the means and adjusted p-values. OR, 
odds ratios with 95% CI, confidence intervals. BMI, body mass index; HbA1c, glycated 
Hemoglobin A1c;  
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Figure 1. 
 
  
452508 
Patient selection 
Number of patients in DPV registry 
341010 Type 1 diabetes 111498 
65979 45519 Age < 20 years 
391 45128 Coeliac disease 
273 44855 Hepatitis 
3 
44296 Alcoholism 
758 43538 
>=24g alcohol (m) 
>=12g alcohol (f) 
Type 2 or other diabetes 
11463 32075 Insulin therapy  
not documented 
22849 9226 
Liver enzymes  
(ALT/AST/GGT) 
reported 
44852 
556 
Alpha-1-antitrypsin 
Liver enzymes  
not reported 
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Table 1. 
 
Datasets Total cohort 
Increased 
Liver enzymes 
Normal 
Liver enzymes 
p-value 
N  
Female (%) 
9226 
9226 
 
46 
1824 
49 
7402  
45 
 
0.2 
Age (yrs) 9226  42.2 (27.1, 56.7) 49.4 (36.0, 61.9) 40.0 (25.7, 54.9) <0.000001 
Migration background (%) 9226 4.0 3.6 4.2 1.0 
Duration of T1DM (yrs) 9226 15.0 (7.1, 25.9) 15.6 (6.5, 28.8) 14.8 (7.3, 25.4) 1.0 
      
BMI (kg/m
2
) 9155 25.0 (22.5, 28.2) 25.7 (22.8, 29.9) 24.8 (22.5, 27.9) <0.000001 
BMI>= 30kg/m
2
 (%) 9155 17 25 15  
Waist circumference (cm) 2198 92 (84, 101) 94 (87, 107) 91 (84, 100) 0.0005 
      
HbA1c (%) 9119 7.9 (7.0, 9.1) 8.1 (7.1, 9.8) 7.8 (6.9, 9.0) <0.000001 
HbA1c (mmol/mol)  62 (53, 76) 65 (54, 83) 62 (52, 75)  
HbA1c <=7.5% (%)  40 34 42  
HbA1c > 9.0% (%)  33 32 24  
Insulin dosis (IU/kg/day) 
 
9226 0.62 (0.46, 0.82) 0.62 (0.46, 0.83) 0.62 (0.46, 0.82) 1.0 
Diabetes therapy 9226     
Conventional insulin therapy 
 
 15% 19% 15% 0.0006 
Intensified insulin therapy 
 
 56% 60% 55% 0.002 
Insulin pump  29% 21% 30% <0.00001 
      
BP systolic/diastolic (mmHg) 9008 126 (119, 138) 
/76 (70, 80) 
130 (120, 140) 
/76 (70, 80) 
125 (119, 137) 
/76 (70, 80) 
<0.0001/ 
1.0 
Total cholesterol (mg/dl) 8409 190 (164, 218) 197 (165, 228) 189 (163, 216) <0.00001 
LDL-cholesterol (mg/dl) 7930 107 (85, 132) 110 (84, 140) 106 (85, 130) 0.02 
HDL-cholesterol (mg/dl) 8034 58 (46, 72) 54 (41, 69) 59 (48, 73) <0.00001 
Triglycerides (mg/dl) 8252 100 (71, 149) 124 (85, 194) 95 (69, 140) <0.00001 
      
ALT (U/l) 8681 20 (15, 29) 38 (25, 58) 19 (14, 24) <0.00001 
AST (U/l) 6717 21 (17, 28) 34 (24, 49) 20 (16, 24) <0.00001 
GGT (U/l) 8432 20 (14, 34) 64 (39, 105) 18 (13, 25) <0.00001 
No alcohol consumption  81% 85% 81% 0.02 
Alcohol consumption g/day 
(in those consuming alcohol)  
925 5 (3, 10) 6 (3, 11) 5 (2,10) 0.2 
      
Myocardial infarction (%) 9226 3.9 6.4 3.2 <0.00001 
Stroke (%) 
Major amputation (%) 
9226 
9226 
2.8 
0.7 
4.1 
1.4 
2.5 
0.5 
0.004 
0.001 
End stage renal disease (%) 9015 2.7 4.1 2.3 0.0004 
      
Hypertension (%) 9082 47 59 44 <0.00001 
Dyslipidemia (%) 8671 63 78 60 <0.00001 
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Table 2. 
 
 
 
 
 
 Increased 
Liver 
enzymes 
Normal 
Liver enzymes 
Adj. p 
value  
Odds Ratio (95% CI) 
Hypertension (%) 
 
57.3±2.1 47.5±1.7 <0.0001 1.48 (1.31-1.68) 
Dyslipidaemia (%) 
 
73.7±1.3 61.5±1.0 <0.0001 1.75 (1.54-2.00) 
Myocardial infarction (%) 
 
2.7± 0.4 1.8±0.2 0.002 1.49 (1.17-1.91) 
Stroke (%) 
 
1.78±0.3 1.5±0.2 0.28 1.17 (0.88-1.60) 
Major amputation (%) 
 
0.66±0.16 0.33±0.07 0.23 1.99 (0.07-57 
End stage renal disease (%) 
 
3.0±0.5 1.9±0.2 0.004 1.59 (1.17-2.17) 
Age * 39.5±0.8 35.5±0.7 <0.0001  
BMI * 26.4±0.1 25.2±0.1 <0.0001  
Insulin dosis (IU/kg/day) * 0.74±0.01 0.71±0.01 <0.0001  
HbA1c (%)* 8.2±0.1 7.9±0.1 <0.0001  
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Table 3. 
Subgroup analysis of patients in whom ALT was increased above 30 U/l in males and 19 
U/l in females on at least two occasions. 
Anthropometric, clinical and laboratory characteristics of the patients with T1DM with 
increased and normal ALT. 
Data are presented as median (Q1, Q3). P-values for subgroup comparisons for continuous 
variables are derived from non-parametric testing applying Wilcoxon tests and from χ
2
 tests 
for binominally distributed variables. P values adjusted for multiple comparisons using the 
Holm method. 
T1DM, type 1 diabetes mellitus; BMI, body mass index; HbA1c, glycated Hemoglobin A1c; BP, blood 
pressure; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; GGT, gamma-glutamyl-
transferase; LDL-cholesterol, low-density lipoprotein cholesterol; HDL-cholesterol, high density lipoprotein 
cholesterol; 
  
Patients with >= 2 ALT 
measurements available 
Increased 
ALT (>=twice) 
Normal 
ALT 
p-value 
 
Total subgroup 
N  
Female (%) 
 686 
56 
1649 
42 
<0.00001 2335 
46 
Age (yrs) 46.1 (31.6, 57.9) 41.0 (26.5, 55.8) <0.002 42.8 (28.2-56.5) 
Migration background 3.0 1.5 0.78 2.5 
Duration of T1DM (yrs) 15.9 (6.5, 27.7) 15.9 (7.8, 26.4) 1.0 15.9 (7.5-26.7) 
     
BMI (kg/m
2
) 26.4 (23.5, 29.9) 25.0 (22.6, 28.0) <0.00001 25.3 (22.9-28.6) 
Waist circumference (cm) 94 (87, 101) 92 (85, 99) 0.15 92 (86-99) 
Insulin dosis (IU/kg/ day) 0.62 (0.47-0.81) 0.62 (0.48-0.81) 1.0 0.62 (0.48-0.81) 
HbA1c (%) 8.2 (7.3, 9.8) 7.8 (7.0, 8.9) <0.000001 7.9 ( 7.1-9.0) 
HbA1c (mmol/mol) 66 (56, 83) 62 (53, 73)  63 (54-75) 
BP systolic/diastolic (mmHg) 125 (120, 137) 
/78 (70, 80) 
125 (118, 134) 
/75 (70, 80) 
0.9/0.9 125 (119-135)/ 
76 (70-80) 
Total cholesterol (mg/dl) 200 (172, 228) 185 (162, 212) <0.000001 189 (164-217) 
LDL-cholesterol (mg/dl) 112 (87, 136) 102 (82, 125) <0.000001 104 (83-128) 
HDL-cholesterol (mg/dl) 57 (46, 74) 59 (48, 72) 1.0 59 (47-73) 
Triglycerides (mg/dl) 108 (74, 162) 95 (70, 138) <0.000001 98 (70-147) 
     
ALT U/l 33 (25, 45) 17 (14, 22) <0.000001 20 (16-28) 
AST U/l 29 (23, 39) 20 (16, 24) <0.000001 21 (17-28) 
GGT U/l 27 (16, 46) 17 (13, 26) <0.000001 19 (13-32) 
     
Myocardial infarction (%) 3.0 4.5 1.0 4.1 
Stroke (%) 
Major amputation (%) 
2.6 
1.0 
2.5 
1.0 
1.0 
1.0 
2.5 
1.0 
End stage renal disease (%) 3.0 3.6 1.0 3.4 
     
Hypertension (%) 57 47 0.0008 50 
Dyslipidemia (%) 76 61 <0.000001 65 
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Table 4.  
Subgroup analysis of patients in whom ALT was increased above 30 U/l in males and 19 
U/l in females on at least two occasions. 
Comparison of prevalence of comorbidities and complications by means logistic regression 
models (with adjustment for age, sex, diabetes duration, migration background, HbA1c and 
treatment center) and of age, BMI, insulin doses and HbA1c using linear regression models 
(*) (with adjustement for age, sex, diabetes duration, migration background, HbA1c and 
treatment center) between patients with increased and with normal ALT.  
Data are presented as means ± standard error of the means and adjusted p-values. 
BMI, body mass index; glycated Hemoglobin A1c;  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Patients with >= 2 ALT 
measurements available 
Increased 
ALT  
(>= twice) 
Normal 
ALT 
 
Adj. p 
value  
Odds Ratio (95% 
CI) 
Hypertension (%) 
 
60.6±3.0 49.4±2.6 <0.0001 1.58 (1.26-1.97) 
Dyslipidaemia (%) 
 
77.9±2.0 65.0±1.9 <0.0001 1.89 (1.51-2.37) 
Myocardial infarction (%) 
 
2.4± 0.6 2.9±0.6 0.37 0.80 (0.50-1.29) 
Stroke (%) 
 
1.1±12 0.8±9.8 0.43 1.27 (0.70-2.33) 
Major amputation (%) 
 
0.74±0.3 0.69 ±0.2 0.89 1.08 (0.003-418) 
End stage renal disease (%) 
 
2.2±0.5 2.7±0.4 0.58 0.81 (0.025-25.9) 
Age * 40.6±1.3 38.1±1.2 <0.0001  
BMI * 26.5±0.2 25.1±0.2 <0.0001  
Insulin dosis (IU/kg/day) * 0.71±0.02 0.70±0.02 0.59  
HbA1c (%)* 8.4±0.1 7.8±0.1 <0.0001  
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Table 5.  
Anthropometric, clinical and laboratory characteristics of the total cohort of patients with 
T1DM in whom liver enzymes were measured compared with patients in whom no liver 
enzyme measurements were available.  
T1DM, type 1 diabetes mellitus; BMI, body mass index; HbA1c, glycated Hemoglobin A1c; BP, blood 
pressure; LDL-cholesterol, low-density lipoprotein cholesterol; HDL-cholesterol, high density lipoprotein 
cholesterol; 
 
Data are presented as median (Q1, Q3). P-values for subgroup comparisons for continuous 
variables are derived from non-parametric testing applying Wilcoxon tests and from χ
2
 tests 
for binominally distributed variables. P values adjusted for multiple comparisons using the 
Holm method. 
 
 
 
Comparison patients with liver 
enzyme measurements available/ 
not available 
Liver enzymes 
measured 
Liver enzymes not 
measured 
p-value 
 
N  
Female (%) 
9226 
46 
22849  
47 
 
1.0 
Age (yrs) 42.2 (27.0, 56.1) 43.6 (28.4, 58.0) <0.0001 
Migration background 4.0% 1.9% <0.0001 
Duration of T1DM (yrs) 15.0 (7.1, 25.9) 15.0 (6.7, 26.7) 1.0 
    
BMI (kg/m
2
) 25.0 (22.5, 28.2) 24.8 (22.3, 28.0) <0.002 
Waist circumference (cm) 92 (84, 101) 89 (81, 98) <0.00001 
    
HbA1c (%) 7.9 (7.0, 9.1) 7.7 (6.8, 9.1) <0.00001 
HbA1c (mmol/mol) 62 (53, 76) 61 (51, 76)  
Insulin dosis (IU/kg/day) 
 
0.62 (0.46, 0.82) 0.61 (0.45, 0.81) 0.004 
BP systolic/diastolic (mmHg) 126 (119, 138) 
/76 (70, 80) 
128 (120, 140) 
/78 (70, 80) 
0.0002/ 
0.001 
Total cholesterol (mg/dl) 190 (164, 218) 190 (163, 220) 1.0 
LDL-cholesterol (mg/dl) 107 (85, 132) 106 (82, 131) 0.1 
HDL-cholesterol (mg/dl) 58 (46, 72) 57 (45, 72) 0.1 
Triglycerides (mg/dl) 100 (71, 149) 106 (74, 159) <0.0001 
    
No alcohol consumption 81% 82% 1.0 
Alcohol consumption g/day 
(in those consuming alcohol)  
5 (3, 10) 5 (3,10) 1.0 
    
Myocardial infarction (%) 3.9 3.7 1.0 
Stroke (%) 
Major amputation (%) 
2.8 
0.7 
2.7 
0.7 
1.0 
1.0 
End stage renal disease (%) 2.7 3.2 0.1 
    
Hypertension (%) 47 41 <0.000001 
Dyslipidemia (%) 63 66 <0.005 
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Table 6. 
Anthropometric, clinical and laboratory characteristics of the patients with T1DM in centers 
where liver enzymes were measured in at least 50% of the patients (83 of the 270 centres) 
compared with patients from centers that measure less frequently. 
T1DM, type 1 diabetes mellitus; BMI, body mass index; HbA1c, glycated Hemoglobin A1c; BP, blood 
pressure; LDL-cholesterol, low-density lipoprotein cholesterol; HDL-cholesterol, high density lipoprotein 
cholesterol; 
 
Data are presented as median (Q1, Q3). P-values for subgroup comparisons for continuous 
variables are derived from non-parametric testing applying Wilcoxon tests and from χ
2
 tests 
for binominally distributed variables. P values adjusted for multiple comparisons using the 
Holm method. 
 
 
 Patients from 
centres with >=50% 
patients liver 
enzymes measured 
Patients from 
centres with <50% 
patients liver 
enzymes measured 
p-value 
 
N  
Female (%) 
 5073 
47 
4153 
45 
 
0.9 
Age (yrs) 41.8 (27.1, 56.1) 42.6 (27.1, 57.4) 1.0 
Migration background 5.6% 2.0% <0.000001 
Duration of T1DM (yrs) 16.0 (7.6, 28.0) 13.9 (6.5, 24.0) <0.000001 
    
BMI (kg/m
2
) 25.0 (22.5, 28.3) 24.9 (22.4, 28.2) 1.0 
Waist circumference (cm) 92 (85, 101) 90 (82, 99) 0.06 
HbA1c (%) 8.0 (7.1, 9.2) 7.6 (6.8, 9.0) <0.000001 
HbA1c (mmol/mol) 63 (54, 78) 60 (51, 74) <0.000001 
BP systolic/diastolic (mmHg) 125 (118, 137) 
/75 (70, 80) 
128 (120, 139) 
/76 (70, 80) 
0.006/0.1 
 
Total cholesterol (mg/dl) 189 (162, 217) 191 (165, 219) 0.2 
LDL-cholesterol (mg/dl) 106 (83, 132) 108 (87, 132) 0.1 
HDL-cholesterol (mg/dl) 58 (47, 72) 58 (46, 72) 1.0 
Triglycerides (mg/dl) 99 (71, 149) 101 (72, 149) 1.0 
    
Heart attack 3.6% 4.2% 1.0 
Stroke 
Major amputation 
2.7% 
0.8% 
3.0% 
0.7% 
1.0 
1.0 
End stage renal disease 3.3% 1.9% 0.0004 
    
Hypertension 49% 44% 0.0003 
Dyslipidemia 63% 63% 1.0 
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